Searched for: in-biosketch:true
person:jad292
Engagement with mHealth-CR Varies Widely Among Older Adults [Meeting Abstract]
Graves, C; Schoenthaler, A; Sweeney, G; Fonceva, A; Whiteson, J; George, B; Marzo, K; Rerisi, E; Kovell, L; Adhikari, S; Dodson, J
Background: Mobile health cardiac rehabilitation (mHealth-CR) may improve outcomes among older adults with ischemic heart disease, but variable engagement is not yet understood. We therefore analyzed preliminary data from the RESILIENT trial, an ongoing randomized trial of mHealth-CR vs. usual care in patients age >= 65.
Method(s): Data from the first 50 intervention participants were analyzed. Weekly engagement was scored from 0-11 based on exercise completion, therapist communication, video viewing, and BP self-measurement. Participants were classified as high or low engagement based on median engagement scores. Groups were compared by age, sex, social support (living alone), depression (PHQ-8), and Charlson Comorbidity Index (CCI).
Result(s): There was widely varying engagement with mHealth-CR that ranged from nearly zero to nearly perfect engagement (Figure). There were no significant differences between high and low engagement groups based on mean age (72.6 vs. 72.8, P=0.8), sex (76% male vs. 80%, P=0.7), living alone (28% vs. 44%, P=0.2), depression (mean 3.9 vs. 4.6, P=0.5), or comorbidity burden (mean 4.4 vs. 4.8, P=0.3), although the sample size was small.
Conclusion(s): Our early findings show wide variation in mHealth-CR engagement among older adults
EMBASE:637954339
ISSN: 1531-5487
CID: 5252422
Medication utilization among vascular dementia population
Razavian, Narges; Dodson, John; Masurkar, Arjun V; Wisniewski, Thomas; Horwitz, Leora; Aphinyanaphongs, Yindalon
BACKGROUND:It is estimated that up to 40% of Alzheimer's Disease and Related Dementias cases can be prevented or delayed by addressing modifiable factors including those that influence vascular risk (hypertension, obesity, smoking, physical activity, diabetes). Prevention may be particularly important in the vascular dementia subtypes. Despite the supporting evidence, the rates of medical therapy to reduce vascular risk are not well described. METHOD/METHODS:We assessed the utilization of statins, aspirin, and blood pressure (BP) medications in adults age ≥65 years cared for at NYU Langone Health, as recorded in the electronic health record. We included two cohorts: cohort 1 included patients who were diagnosed with vascular dementia (VaD) at NYU Langone Barlow Center for Memory Evaluation between January 1, 2015 and June 24, 2019. Cohort 2 extended the inclusion to seniors with VD diagnosis by any NYU Langone physician. Definitions for vascular dementia, the covariates assessed, and medications that we included in each category are shown in Tables 1-3. RESULT/RESULTS:We included 419 and 3745 patients in cohort 1 and cohort 2, respectively. Table 4 shows the characteristics and medication adherence in cohorts 1 and 2. In cohort 1, the prescription rates for statins, aspirin, and BP medications were 66%, 66%, 70%. In cohort 2, the rates for statin, aspirin, and BP medications were 56%, 46%, and 65%, respectively. The differences between prescription rates in cohort 1 and 2 for the three medication groups were statistically significant (p<0.05). CONCLUSION/CONCLUSIONS:Our analysis of the utilization of cardiovascular medications among patients with vascular dementia illuminates potential gaps both among patients who receive care at specialty clinics, as well as the overall population with vascular dementia. The rates of medication utilization are higher for patients under the care of cognitive neurologists. Electronic health records can help identify large cohorts of patients who may benefit from improved access to preventative measures including cardiovascular medications.
PMID: 34971267
ISSN: 1552-5279
CID: 5108332
Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction
Mohanty, April F; Levitan, Emily B; King, Jordan B; Dodson, John A; Vardeny, Orly; Cook, James; Herrick, Jennifer S; He, Tao; Patterson, Olga V; Alba, Patrick R; Russo, Patricia A; Obi, Engels N; Choi, Michelle E; Fang, James C; Bress, Adam P
Background Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF). Our objective was to describe the sacubitril/valsartan initiation rate, associated characteristics, and 6-month follow-up dosing among veterans with HFrEF who are renin-angiotensin-aldosterone system inhibitor (RAASi) naïve. Methods and Results Retrospective cohort study of veterans with HFrEF who are RAASi naïve defined as left ventricular ejection fraction (LVEF) ≤40%; ≥1 in/outpatient heart failure visit, first RAASi (sacubitril/valsartan, angiotensin-converting enzyme inhibitor [ACEI]), or angiotensin-II receptor blocker [ARB]) fill from July 2015 to June 2019. Characteristics associated with sacubitril/valsartan initiation were identified using Poisson regression models. From July 2015 to June 2019, we identified 3458 sacubitril/valsartan and 29 367 ACEI or ARB initiators among veterans with HFrEF who are RAASi naïve. Sacubitril/valsartan initiation increased from 0% to 26.5%. Sacubitril/valsartan (versus ACEI or ARB) initiators were less likely to have histories of stroke, myocardial infarction, or hypertension and more likely to be older and have diabetes mellitus and lower LVEF. At 6-month follow-up, the prevalence of ≥50% target daily dose for sacubitril/valsartan, ACEI, and ARB initiators was 23.5%, 43.2%, and 47.1%, respectively. Conclusions Sacubitril/valsartan initiation for HFrEF in the Veterans Administration increased in the 4 years immediately following Food and Drug Administration approval. Sacubitril/valsartan (versus ACEI or ARB) initiators had fewer baseline cardiovascular comorbidities and the lowest proportion on ≥50% target daily dose at 6-month follow-up. Identifying the reasons for lower follow-up dosing of sacubitril/valsartan could support guideline recommendations and quality improvement strategies for patients with HFrEF.
PMID: 34612065
ISSN: 2047-9980
CID: 5061862
Perioperative cardiovascular outcomes among older adults undergoing in-hospital noncardiac surgery
Banco, Darcy; Dodson, John A; Berger, Jeffrey S; Smilowitz, Nathaniel R
BACKGROUND:Older adults undergoing noncardiac surgery have a high risk of major adverse cardiovascular events (MACE). This study aims to estimate the magnitude of increased perioperative risk, and examine national trends in perioperative MACE following in-hospital noncardiac surgery in older adults compared to middle-aged adults. DESIGN/METHODS:Time-series analysis of retrospective longitudinal data. SETTING/METHODS:The United States Agency for Healthcare Research and Quality National Inpatient Sample (NIS). PARTICIPANTS/METHODS:Hospitalizations for major noncardiac surgery among adults age ≥45 years between January 2004 and December 2014. MEASUREMENTS/METHODS:Inpatient perioperative MACE was defined as a composite of in-hospital death, myocardial infarction (MI), and ischemic stroke. In hospital death was determined from the NIS discharge disposition. MI and ischemic stroke were defined by International Classification of Diseases, Ninth Revision codes. RESULTS:Of an estimated 55,349,978 surgical hospitalizations, 26,423,039 (47.7%) were for adults age 45-64, 14,231,386 (25.7%) age 65-74, 10,621,029 (19.2%) age 75-84 years, and 4,074,523 (7.4%) age ≥85 years. MACE occurred in 1,601,022 surgical hospitalizations (2.9%). Adults 65-74 (2.8%; aOR 1.16, 95% CI 1.14-1.17), 75-84 years (4.5%; aOR 1.30, 95% CI 1.28-1.32), and ≥85 years (6.9%; aOR 1.55, 95% CI 1.52-1.57) had greater risk of MACE than those 45-64 years (1.7%). From 2004 to 2014, MACE declined among adults 65-74 (3.1-2.5%, p < 0.001), 75-85 years (4.9-3.9%, p < 0.001), and ≥85 years (7.7-6.1%, p < 0.001), but was unchanged for adults age 45-64. Declines in MACE were driven by decreased MI and mortality despite increased stroke. CONCLUSION/CONCLUSIONS:Older adults accounted for half of hospitalizations, but experienced the majority of MACE. Older adults had greater adjusted odds of MACE than younger individuals. The proportion of perioperative MACE declined over time, despite increases in ischemic stroke. These data highlight risks of noncardiac surgery in older adults that warrant increased attention to improve perioperative outcomes.
PMID: 34176124
ISSN: 1532-5415
CID: 4965592
Validation of EHR medication fill data obtained through electronic linkage with pharmacies
Blecker, Saul; Adhikari, Samrachana; Zhang, Hanchao; Dodson, John A; Desai, Sunita M; Anzisi, Lisa; Pazand, Lily; Schoenthaler, Antoinette M; Mann, Devin M
PMID: 34595945
ISSN: 2376-1032
CID: 5050062
Relation of the Number of Cardiovascular Conditions and Short-term Symptom Improvement After Percutaneous Coronary Intervention for Stable Angina Pectoris
Flynn, Christopher R; Orkaby, Ariela R; Valsdottir, Linda R; Kramer, Daniel B; Ho, Kalon K; Dodson, John A; Yeh, Robert W; Strom, Jordan B
With aging of the population, cardiovascular conditions (CC) are increasingly common in individuals undergoing PCI for stable angina pectoris (AP). It is unknown if the overall burden of CCs associates with diminished symptom improvement after PCI for stable AP. We prospectively administered validated surveys assessing AP, dyspnea, and depression to patients undergoing PCI for stable AP at our institution, 2016-2018. The association of CC burden and symptoms at 30-days post-PCI was assessed via linear mixed effects models. Included individuals (N = 121; mean age 68 ± 10 years; response rate = 42%) were similar to non-included individuals. At baseline, greater CC burden was associated with worse dyspnea, depression, and physical limitations due to AP, but not AP frequency or quality of life. PCI was associated with small improvements in AP and dyspnea (p ≤ 0.001 for both), but not depression (p = 0.15). After multivariable adjustment, including for baseline symptoms, CC burden was associated with a greater improvement in AP physical limitations (p = 0.01) and depression (p = 0.002), albeit small, but not other symptom domains (all p ≥ 0.05). In patients undergoing PCI for stable AP, increasing CC burden was associated with worse dyspnea, depression, and AP physical limitations at baseline. An increasing number of CCs was associated with greater improvements, though small, in AP physical limitations and depression. In conclusion, the overall number of cardiovascular conditions should not be used to exclude patients from PCI for stable AP on the basis of an expectation of less symptom improvement.
PMCID:8384702
PMID: 34281673
ISSN: 1879-1913
CID: 4981422
Presentation, Treatment, and Outcomes of Older Adults Hospitalized for Acute Myocardial Infarction According to Cognitive Status: The SILVER-AMI Study
Hajduk, Alexandra M; Saczynski, Jane S; Tsang, Sui; Geda, Mary E; Dodson, John A; Ouellet, Gregory M; Goldberg, Robert J; Chaudhry, Sarwat I
BACKGROUND:While survival after acute myocardial infarction has improved substantially, older adults remain at heightened risk for hospital readmissions and death. Evidence for the role of cognitive impairment in older myocardial infarction survivors' risk for these outcomes is limited. METHODS:3041 patients aged ≥75 years hospitalized with acute myocardial infarction (mean age 82 ± 5 years, 56% male) recruited from 94 US hospitals. Cognition was assessed using the Telephone Interview for Cognitive Status; scores of <27 and <22 indicated mild and moderate/severe impairment, respectively. Readmissions and death at 6 months post-discharge were ascertained via participant report and medical record review. Associations between cognition and outcomes were evaluated with multivariable-adjusted logistic regression. RESULTS:Mild and moderate/severe cognitive impairment were present in 11% and 6% of the cohort, respectively. Readmission and death at 6 months occurred in 41% and 9% of participants, respectively. Mild and moderate/severe cognitive impairment were associated with increased risk of readmission (odds ratio [OR] 1.36; 95% confidence interval [CI], 1.08-1.72 and OR 1.58; 95% CI, 1.18-2.12, respectively) and death (OR 2.19; 95% CI, 1.54-3.11 and OR 3.82; 95% CI, 2.63-5.56, respectively) in unadjusted analyses. Significant associations between moderate/severe cognitive impairment and death (OR 1.69; 95% CI, 1.10-2.59) persisted after adjustment for demographics, myocardial infarction characteristics, comorbidity burden, functional status, and depression, but not for readmissions. CONCLUSIONS:Moderate-to-severe cognitive impairment is associated with heightened risk of death in older acute myocardial infarction patients in the months after hospitalization, but not with readmission. Routine cognitive screening may identify older myocardial infarction survivors at risk for poor outcomes who may benefit from closer oversight and support in the post-discharge period.
PMID: 33737057
ISSN: 1555-7162
CID: 4889012
RACIAL DISPARITIES IN FUNCTIONAL IMPAIRMENTS AMONG OLDER ADULTS HOSPITALIZED FOR ACUTE MYOCARDIAL INFARCTION: THE SILVER-AMI STUDY [Meeting Abstract]
Demkowicz, P; Hajduk, A; Dodson, J; Oladele, C R; Chaudhry, S
Background Racial disparities in age-associated functional impairments, which are powerful predictors of readmission and mortality after acute myocardial infarction (AMI), have not been described in older AMI patients. Given an aging population and growing recognition of the prognostic value of functional impairments, this is an important knowledge gap. Methods We analyzed data from SILVER-AMI, a prospective cohort study that enrolled patients aged >=75 hospitalized for AMI at 94 sites across the US. Patients were assessed for functional impairments during hospitalization. Patients completed an in-person Telephone Interview for Cognitive Status, a Timed Up and Go test of mobility and a grip strength test. Vision and hearing impairments were self-reported. Patients also reported their prehospital independence in activities of daily living (bathing, dressing, ambulating, rising from a chair). We evaluated racial disparities in functional impairments using Pearson's chi-squared test with Yates' continuity correction. Results Of 3,041 patients, 2,668 (87.7%) identified as white and 325 (10.7%) identified as another race (250 Black, 40 Asian, 15 American Indian or Alaskan Native, 8 Native Hawaiian or Pacific Islander, 12 two or more races). Nonwhite patients were younger (80.9 yr. vs. 81.7 yr.; p<0.01), less likely to have a college degree (35.7% vs. 43.5%; p<0.05) and more often female (59.7% vs. 42.5%; p<0.001). Cognitive impairment was more common among nonwhite patients (35.1% vs. 14.5%; p<0.001), as was mobility impairment (64.3% vs. 54.6%; p<0.001). Weak grip was similarly prevalent in both groups (63.1% vs. 59.4%; p=0.29). Vision impairment was more common among nonwhite patients (50.2% vs. 35.7%; p<0.001), while hearing impairment was less common (38.5% vs. 55.7%; p<0.001). Nonwhite patients were more likely to report a disability in one or more activities of daily living (21.2% vs. 13.0%; p<0.001). Conclusion In this well-characterized AMI cohort, nonwhite patients had a more "geriatric" phenotype despite a younger age, with more functional impairments (cognition, mobility, vision) and a higher rate of disability in one or more activities of daily living.
Copyright
EMBASE:2011744076
ISSN: 0735-1097
CID: 4884662
CARDIAC REHABILITATION IMPROVES FUNCTIONAL CAPACITY IN PATIENTS WITH ADULT CONGENITAL HEART DISEASE [Meeting Abstract]
Sheng, S; Feinberg, J; Bostrom, J; Tang, Y; Sweeney, G; Pierre, A; Katz, E; Whiteson, J; Haas, F; Dodson, J; Halpern, D
Background Cardiac rehabilitation (CR) is increasingly being prescribed for adult congenital heart disease (ACHD) patients after cardiac procedures or for reduced exercise tolerance. We aim to describe the functional capacity improvements of ACHD patients in CR. Methods This retrospective study included ACHD patients at NYU Rusk Cardiac Rehabilitation from 2013-2019. We collected data on patient characteristics, number of sessions attended, and exercise testing results. Paired sample t-tests were used to assess for changes between pre- and post-CR exercise time and metabolic equivalents (METs). Results In total, 76 ACHD patients (mean age 38.2 years, 56.6% female, 89.5% moderate or complex conditions by anatomic classification) participated in CR. Referral indication was reduced exercise tolerance for 43.4% and was post-cardiac procedure (transcatheter or surgical) for the remainder. Among 37 patients (48.7%) who finished all 36 CR sessions, complete exercise testing data was available for 29 of them. Exercise time increased by 83.8 seconds (95% CI, 43.9 - 123.8; baseline mean 520.7), METs increased by 1.2 (95% CI, 0.6 - 1.8; baseline mean 8.1), and both parameters increased for 72.4% of these patients. These statistically significant improvements were observed across referral indications. Conclusion On average, CR benefits ACHD patients who complete the program, regardless of referral indication. Efforts to increase CR referral and retention would allow more patients to benefit. [Formula presented]
Copyright
EMBASE:2011750530
ISSN: 0735-1097
CID: 4884642
Aspirin, Statins, and Primary Prevention: Opportunities for Shared Decision Making in the Face of Uncertainty
Jhaveri, Amit; Sibley, Rachel A; Spatz, Erica S; Dodson, John
PURPOSE OF REVIEW:The utility of aspirin and statins for primary prevention of atherosclerotic cardiovascular disease remains ambiguous in older adults. Current guidelines and recent data are vague and inconclusive. This review seeks to summarize the landscape of primary prevention of cardiovascular disease in older adults and explore the role of shared decision making. RECENT FINDINGS:Observational data suggest potential benefit of statin therapy in older adults. Aspirin is presently not recommended for primary prevention based on evidence from recent clinical trials. The implementation of shared decision making and decision aids in routine clinical practice remains challenging but may rise in coming years. Clinical trial data on the horizon may aid in solidifying guideline therapy for statin use. However, in the face of uncertainty, shared decision making between provider and patient should be utilized to determine whether pharmacotherapy may benefit older adults. Decision aids are an effective tool to guide this process.
PMID: 33961154
ISSN: 1534-3170
CID: 4874122